Bolt Biotherapeutics

Avatar photo
Ad disclosure TrustPedia is an independent platform with the mission of simplifying financial decisions. Therefore, we work with independent professionals to offer you the latest news. We may receive compensation if you click on certain links, sponsored posts, products and/or services, transferring leads to brokers, or advertisements. We do our utmost best to ensure you will not incur any disadvantages as a user. No rights can be derived from the Content we provided on or through our website, nor should this be considered as legal, tax, investment, financial or other advice. The Content is for informational purposes only. In case of any doubt, you should seek advice from an independent financial advisor. Read More >>

BOLT Biotherapeutics (est. 2015) is a world-class pioneer of targeted immunotherapy whose influence in the health sector has been incredible. This company consists of intelligent innovators whose primary goal is to provide transformative treatments for people living with cancer and those with limited or unavailable medical solutions. It is a biotech company founded by Dr. Edgar G. Engleman, a Stanford University graduate whose work in cancer immunotherapeutics and myeloid biology has received massive recognition.

BOLT Biotherapeutics is made up of a team of professionals who have helped the company build a huge pipeline of immune-stimulating, myeloid-engaging therapeutics using its leading product, BoltBody ISAC (BDC-1001). This PD-L1-approved drug has gone through a preclinical stage to refractory checkpoint tumors such as non-small cell lung cancer, breast cancer, and head and neck cancer. Currently, it is in a multi-arm phase ½ trial to target HER2 tumors (HER2+ gastric, breast, and HER2- breast cancer). It also has a myeloid-modulating agonist antibody (BDC-3042) to target dectin-2, i.e., solid tumors with unmet needs but still remains in a preclinical stage.

In 2021, the company listed its initial public offering to raise $150M from the sales of 8.825M BOLT at $17 per share. However, it raised $230M from 11.5M common stock at $20 per share. BOLT Biotherapeutics planned to use proceeds from the offering to fund clinical research and development of BDC-1001, which was at its phase 1/2 trial. It also planned to use part of the fund to complete IND-enabling studies, initiation of BDC-2034 clinical development, and the rest for PD-L1 ISAC and TAM1 research and development.

Find out what has happened to the stocks so far since the first listing and its forecasts in this article.

BOLT Stock Forecast 2022

12 Stock Analysts predicted BOLT Biotherapeutics stocks, BOLT, will be $6.8 over the next 12 months, i.e., 2023. This stock price will be a 431.25% increase from its current price ($1.31), with the lowest at $4.04 and the highest at $8.4. It is forecasted to beat the market by 2023, affecting its revenue growth and earnings per share. Wall Street analysis also thinks that Bolt Biotherapeutic’s share in 2023 could reach $7.67, an increase of 485.27% from its current price ($1.31).
These two analyses only prove that BOLT stock is a good buy over the next 1 year. Even though it opened the year at $4.87 and experienced a serious downfall in the latter parts of 2022, BOLT still has a chance to get back on track in the following years.

BOLT Stock 2021

12 Stock Analysts predicted BOLT Biotherapeutics stocks, BOLT, will be $6.8 over the next 12 months, i.e., 2023. This stock price will be a 431.25% increase from its current price ($1.31), with the lowest at $4.04 and the highest at $8.4. It is forecasted to beat the market by 2023, affecting its revenue growth and earnings per share. Wall Street analysis also thinks that Bolt Biotherapeutic’s share in 2023 could reach $7.67, an increase of 485.27% from its current price ($1.31).
These two analyses only prove that BOLT stock is a good buy over the next 1 year. Even though it opened the year at $4.87 and experienced a serious downfall in the latter parts of 2022, BOLT still has a chance to get back on track in the following years.

How to Invest in BOLT Stocks

No investor puts money into a business without doing research. Whilst there are plenty of ways to invest in BOLT stocks, one reasonable thing to do first is to familiarize yourself with the stock’s performance since its IPO. This detail is important not only to make logical decisions but to be sure if it is a stock that aligns with your financial goals. Likewise, research gives better insight into what BOLT Biotechnology has to offer and how it will influence stock prices in the future.

So, while you understand BOLT stock investment, you should consider eToro, a reliable online broker. Having a dedicated broker account on this platform is beneficial, such that you get materials and resources on stocks and enough technical analysis for investing. It is your one chance at becoming a better investor.

Without further ado, here is how to create a dedicated online broker account on eToro.

Step 1: Open an Account

Visit the eToro platform and fill out the application form requesting important details.

https://www.etoro.com/customer-service/how-to-open-etoro-account/

Open an Account
Create Account

Step 2: Upload ID

Agree to KYC and AML regulations and confirm your identity by uploading a valid ID – driver’s license or international passport. You also need to upload proof of address.

https://www.etoro.com/customer-service/how-to-open-etoro-account/

Proof of identity

Step 3: Make a Deposit

Get funds in your eToro balance to start investing in BOLT stocks. MasterCard and Visa are approved payment methods to deposit money.

https://www.etoro.com/customer-service/deposit-faq/

Make a Deposit

Step 4: Search for BOLT

Go to the search bar and enter “BOLT.”

https://www.etoro.com/discover

Step 5: Buy BOLT stocks

When you get a result for BOLT stocks, select the “BUY” button. You could buy as much as your funds can support. Wait a few minutes until you can confirm that BOLT stocks have been bought.

Conclusion

What BOLT Biotherapeutics does is phenomenal. Having a company interested in biotech solutions for cancer and diseases with unmet needs is such a rare opportunity. However, there is only so little this company can do, especially regarding research and development, initiation of a treatment stage, and corporate works. Therefore, the company decided to list BOLT stocks to invite people to invest and make short-term or long-term profits.
BOLT Biotherapeutics Inc. plans to use proceeds to launch various projects, which shows that its future plans are great. After reading this article, you should spend a few more hours researching and then create an account on eToro to start trading.

FAQ

  1. Is BOLT Stock Good to Buy in 2022?

    From technical analysis, BOLT seems like a good buy in 2022 and beyond. The stock price is predicted to increase by 485.27% its current price in 2023.

  2. Is BOLT listed on NYSE?

    Yes, it is.

  3. Does the Company Review Its Own Stock Price?

    Bolt Biotherapeutics Inc. has a dedicated page that displays the stock’s quote and chart information.

Risk Disclaimer

TrustPedia is a financial portal-based research agency. We do our utmost best to offer reliable and unbiased information about crypto, finance, trading and stocks. However, we do not offer financial advice and users should always carry out their own research.

Read More